Jackson B Gibbs

US Patent:

6989383, Jan 24, 2006

Filed:

Jun 4, 1998

Appl. No.:

09/445054

Inventors:

Neal Rosen - Englewood NJ, US
Laura Sepp-Lorenzino - New Haven CT, US
Mark M. Moasser - New York NY, US
Allen I. Oliff - Gwynedd Valley PA, US
Jackson B. Gibbs - Chalfont PA, US
Nancy Kohl - Wyndmoor PA, US
Samuel L. Graham - Schwenksville PA, US
George C. Prendergast - Bala Cynwyd PA, US

Assignee:

Sloan-Kettering Institute For Cancer Research - New York NY

International Classification:

A61K 31/495
A61K 31/50
A61K 31/335
A61K 31/35
A61K 31/34

US Classification:

51425405, 51425501, 51425502, 514449, 514459, 514471, 514616

Abstract:

The present invention relates to methods of treating cancer using a combination of a compound which is an antineoplastic agent and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at lest two therapeutic agents selected from a group consisting of a compound which is an antineoplastic agent and a compound which is an inhibitor or prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

US Patent:

20050137207, Jun 23, 2005

Filed:

Feb 15, 2005

Appl. No.:

11/059084

Inventors:

Neal Rosen - Englewood NJ, US
Laura Sepp-Lorenzino - Landsdale PA, US
Mark Moasser - San Francisco CA, US
Allen Oliff - Gwynedd Valley PA, US
Jackson Gibbs - Chalfont PA, US
Nancy Kohl - Wellesley MA, US
Samuel Graham - Schwenksville PA, US
George Prendergast - Bala-Cynwyd PA, US

International Classification:

A61K031/496
A61K031/495

US Classification:

514253010, 514255010, 514254050

Abstract:

The present invention relates to methods of treating cancer using a combination of a compound which is an antineoplastic agent and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is an antineoplastic agent and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

US Patent:

20090062302, Mar 5, 2009

Filed:

Jan 22, 2007

Appl. No.:

12/223043

Inventors:

Carolyn A. Buser-Doepner - Harleysville PA, US
Steven J. Freedman - Ambler PA, US
Jackson B. Gibbs - Chalfont PA, US
Frank J. Giles - Bellaire TX, US
Christopher G. Marshall - Framingham MA, US
John R. Pollard - Oxfordshire, GB

International Classification:

A61K 31/506
A61P 35/02

US Classification:

51425219

Abstract:

The present invention provides methods for inhibiting JAK2 tyrosine kinase. Further, the present invention also provides methods of treating or preventing myeloproliferative disorders.

US Patent:

20100324063, Dec 23, 2010

Filed:

Aug 5, 2010

Appl. No.:

12/850920

Inventors:

Carolyn A. Buser-Doepner - Harleysville PA, US
Steven J. Freedman - Ambler PA, US
Jackson B. Gibbs - Chalfont PA, US
Frank J. Giles - Bellaire TX, US
Christopher G. Marshall - Framingham MA, US
John R. Pollard - Abingdon, GB

International Classification:

A61K 31/496
A61P 35/02
A61P 7/00
C12N 9/99

US Classification:

51425219, 435184

Abstract:

The present invention provides methods for inhibiting JAK2 tyrosine kinase. Further, the present invention also provides methods of treating or preventing myeloproliferative disorders.

US Patent:

58211187, Oct 13, 1998

Filed:

Apr 24, 1995

Appl. No.:

8/424268

Inventors:

Charles A. Omer - Lansdale PA
Ronald E. Diehl - Line Lexington PA
Jackson B. Gibbs - Chalfont PA
Nancy E. Kohl - Wyndmoor PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12N 121
C12N 910
C12N 1554

US Classification:

4353201

Abstract:

The present invention relates to an assay useful in determining the farnesyl-protein transferase inhibitory activity of pharmaceutical agents. The assay employs purified human farnesyl-protein transferase which is prepared by gene expression in Escherichia coli.

US Patent:

55191630, May 21, 1996

Filed:

Oct 15, 1993

Appl. No.:

8/138133

Inventors:

Jackson B. Gibbs - Chalfont PA
Kenneth S. Koblan - Chalfont PA
Angus M. MacLeod - Bishops Stortford, GB
Kevin J. Merchant - Bishops Stortford, GB

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07F 938
A61K 3166

US Classification:

562 23

Abstract:

Novel. alpha. -hydroxyphosphonate compounds which inhibit mammalian phosphoinositide-specific phospholipase-C. The compounds are potent anti-inflammatory and analgesic agents and may be useful for the treatment of cancer.

US Patent:

54708320, Nov 28, 1995

Filed:

Jan 31, 1994

Appl. No.:

8/189772

Inventors:

Jackson B. Gibbs - Chalfont PA
Samuel L. Graham - Schwenksville PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3800
C07K 500
C07K 700
C07K 1700

US Classification:

514 18

Abstract:

The compounds disclosed am analogs of the CAAX motif of proteins that can be modified by geranylgeranylation in vivo that selectively inhibit the geranylgeranylation of several proteins. The relatively poor activity of the compounds against the farnesyl protein transferase, which modifies several proteins important in cellular replication, allows the use of the compounds of the instant invention to treat diseases which which am regulated by the function of a geranylgeranylated protein, such as certain cancers and inflammatory diseases. Further contained in this invention are chemotherapeutic compositions containing these geranylgeranyl protein transfcrase type I inhibitors and methods for their production.